Evidence map›Paper›PMID 36510214›Full record

ArticleTrials2022

Approaches to prioritising research for clinical trial networks: a scoping review.

Rachael L Morton, Haitham Tuffaha, Vendula Blaya-Novakova, Jenean Spencer, Carmel M Hawley, Phil Peyton, Alisa Higgins, Julie Marsh, William J Taylor, Sue Huckson and 7 more

Abstract readScoping Review
In one paragraph

Article in Trials, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Decentralized Clinical Trials in Early Drug Development-A Framework Proposal.Journal of immunotherapy and precision oncology · 2024
    Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Rachael L MortonNational Health and Medical Research Council Clinical Trials Centre (NHMRC CTC), University of Sydney, Sydney, Australia. rachael.morton@sydney.edu.au.ORCID http://orcid.org/0000-0001-7834-0572
Haitham TuffahaCentre for the Business and Economics of Health, University of Queensland, Brisbane, Australia.
Vendula Blaya-NovakovaNational Health and Medical Research Council Clinical Trials Centre (NHMRC CTC), University of Sydney, Sydney, Australia.
Jenean SpencerAustralian Clinical Trials Alliance (ACTA), Melbourne, Victoria, Australia.
Carmel M HawleyAustralasian Kidney Trials Network (AKTN), Faculty of Medicine, University of Queensland, Brisbane, Australia.
Phil PeytonAustralian and New Zealand College of Anaesthetists (ANZCA), Melbourne, Australia.
Alisa HigginsAustralian and New Zealand Intensive Care Research Centre (ANZIC-RC), Monash University, Melbourne, Victoria, Australia.
Julie MarshTelethon Kids Institute, West Perth, Australia.
William J TaylorUniversity of Otago, Rehabilitation Teaching and Research Unit, Dunedin, New Zealand.
Sue HucksonAustralian and New Zealand Intensive Care Society (ANZICS), Camberwell, Victoria, Australia.
Amy SillettAstraZeneca Australia, Macquarie Park, New South Wales, Australia.
Kieran SchneemannAustralian Clinical Trials Alliance (ACTA), Melbourne, Victoria, Australia.
Anitha BalagurunanthanAustralian Clinical Trials Alliance (ACTA), Melbourne, Victoria, Australia.
Miranda CumpstonAustralian Clinical Trials Alliance (ACTA), Melbourne, Victoria, Australia.
Paul A ScuffhamCentre for the Business and Economics of Health, University of Queensland, Brisbane, Australia.
Paul GlasziouFaculty of Health Sciences & Medicine, Bond University, Gold Coast, Australia.
Robert J SimesNational Health and Medical Research Council Clinical Trials Centre (NHMRC CTC), University of Sydney, Sydney, Australia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundPrioritisation of clinical trials ensures that the research conducted meets the needs of stakeholders, makes the best use of resources and avoids duplication. The aim of this review was to identify and critically appraise approaches to research prioritisation applicable to clinical trials, to inform best practice guidelines for clinical trial networks and funders.

methodsA scoping review of English-language published literature and research organisation websites (January 2000 to January 2020) was undertaken to identify primary studies, approaches and criteria for research prioritisation. Data were extracted and tabulated, and a narrative synthesis was employed.

resultsSeventy-eight primary studies and 18 websites were included. The majority of research prioritisation occurred in oncology and neurology disciplines. The main reasons for prioritisation were to address a knowledge gap (51 of 78 studies [65%]) and to define patient-important topics (28 studies, [35%]). In addition, research organisations prioritised in order to support their institution's mission, invest strategically, and identify best return on investment. Fifty-seven of 78 (73%) studies used interpretative prioritisation approaches (including Delphi surveys, James Lind Alliance and consensus workshops); six studies used quantitative approaches (8%) such as prospective payback or value of information (VOI) analyses; and 14 studies used blended approaches (18%) such as nominal group technique and Child Health Nutritional Research Initiative. Main criteria for prioritisation included relevance, appropriateness, significance, feasibility and cost-effectiveness.

conclusionCurrent research prioritisation approaches for groups conducting and funding clinical trials are largely interpretative. There is an opportunity to improve the transparency of prioritisation through the inclusion of quantitative approaches.

Indexed as

Research DesignChildClinical Trials as TopicHumansProspective StudiesClinical trial networksCost-effectivenessPrioritisationReview

Identifiers

PMID36510214
PMCPMC9743749

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.